Zoetis (ZTS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$9.5B

Revenue (quarter)

$2.5B

Revenue growth (year over year)

−0.24%

Gross profit (trailing twelve months)

$6.8B

Gross margin

71.67%

Net income (trailing twelve months)

$2.6B

Net income (quarter)

$691.0M

Net income growth (year over year)

−4.82%

Net margin

27.69%

Return on equity

64.91%

EPS (trailing twelve months)

$6.13

Book value per share

$7.60

P/E (trailing twelve months)

11.80

Price to book

9.88

Debt to assets

79.12%

Payout ratio

33.29%

Dividend yield

2.86%

Company profile

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

• Is Zoetis (ZTS) profitable?

  Yes. Zoetis earned $2.6B in net income over the trailing twelve months, a net margin of 27.69%.

• How much revenue does Zoetis (ZTS) make?

  Zoetis generated $9.5B in revenue over the trailing twelve months, down 0.24% year over year.

• What is ZTS's P/E ratio?

  Zoetis trades at 11.8 times trailing twelve-month earnings, on an EPS of $6.13.

• How do I buy stock in Zoetis (ZTS)?

  ZTS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.